The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan (HRCT) imaging biomarkers as a co-primary endpoint OXFORD, England and CHICAGO, Jan. 20, 2026 /PRNewswire/ -- Brainomix, a global leader and pioneer of...
Hence then, the article about brainomix e lung ai imaging technology selected as co primary endpoint in boehringer ingelheim phase 3 clinical trial in pulmonary fibrosis was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis )
Also on site :
- Naguib Sawiris boosts funding for Egypt’s pyramids facilities development
- Trump attacks ‘communists.’ Both want a bigger government role in the economy.
- Muscat Stock Exchange Index Rises 0.101%